Did Asembia 2016 accelerate the drive to value?

However novel they appear, "at-risk," “outcomes based” contracts between pharmaceutical manufacturers and payers are still based on rudimentary volumetric math.

Traditional contracts bring rebates based on volume and the right place on the formulary. “At-risk” contracts bring higher payment for improving patient outcomes. But as the only drug on formulary, manufacturers are still banking on a simple volumetric percentage of efficacy to meet payment and profit goals.

Did you attend Asembia 2016? You can still connect with Curant Health President and CEO Patrick Dunham and COO Marc O'Connor. You can also view Patrick's presentation from Asembia 2016.

Read our pre-conference blog: The Struggle for Alignment in the Pharmaceutical Industry Remains. Will Asembia 2016 Accelerate Our Drive to Value?

Read our post-conference blog: Learnings from the 2016 Asembia Specialty Pharmacy Summit

“Pharma Manufacturers’ At-Risk Day Has Arrived: Are You Ready?”

Thursday, May 5, 2016

Patrick Dunham, President and CEO of Curant Health with Javier Menendez, VP of Pharmacy Operations for Virginia Premier Health Plan and Joff Masukawa, founder of Diligentia and a member of the board of directors of the Center for Healthcare Innovation.

profile_pic_Patrick_Dunham

stock-photo-11186389-bucket-of-money

Payers: You need to keep costs low for your plan sponsors and derive the greatest value from high cost specialty therapies.

What should your top 3 metrics for therapy approval for chronically ill patients be?

Curant’s medication management protocols and patient support services are proven to improve adherence (a $100-$300 billion source of wasted healthcare spending) and reduce overall healthcare costs.

Manufacturers: You need to prove the efficacy of your therapies in real world conditions.

How will you measure and deliver value that validates the prices of your therapies?

Our medication management protocols and patient support services provide near clinical-trial conditions in real world situations for chronically ill patients on multiple medications.

Payor_Benefits_blurb

Real improvements in outcomes and value-based contracts require more lifestyle factor measurement and corresponding agreement on their evaluation.

There are some outcomes that are easy to measure: hospital readmissions, HCV cure rates and diabetes A1C counts for example What’s not easy, and what is desperately needed for collective advancement, are outcomes that are lifestyle dependent and involve some sort of care team.

Derive the greatest value from specialty medications for the most difficult to treat, chronically ill patients.

Contact Kristin Lindsey at klindsey@curanthealth.com or call (866) 437-8040 extension 253.
armada 2016

“Oncology Pipeline: Who’s Paying For It?”

Thursday, May 5, 2016

Marc O’Connor, COO of Curant Health with Jason Gomberg, Michael Hunter, Paul Jardina and Elvin Montanez who will discuss the oncology pipeline and the forecasted shift in the payer mix.

 
EmailEmailEmailEmail
Menu Title